ICMJE DISCLOSURE FORM

Date:	5 th January 2023
Your Name:	lain Phillips
Manuscript Title:	Clinical impact of cachexia biomarkers in advanced cancer
Manuscript number (if known): APM-22-1416

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None MSD	grant for prehab clinic
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for	MSD	Prehab round table
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Astra Zeneca	Chair of stage 3 meeting
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
		Takeda	Attending communication course
8	Patents planned, issued or	None	
	pending		
_			
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author reports that he received grant for prehab clinic from MSD, honoraria for prehab round table from MSD and for serving as chair of stage 3 meeting from Astra Zeneca; he also received support for attending communication course from Takeda.

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date	e:5 th January 2023 _.		
You	r Name:Mar	k Stares	
Man	nuscript Title: Clin	ical impact of cachexia	biomarkers in advanced cancer
Man	nuscript number (if known):	APM-22-1416)
relat part to tr	ted to the content of your m ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all supp time frame for disclosure is		l in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	

_None

				_
	Payment or honoraria for			
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	xNone		
	testimony			
7	Support for attending meetings and/or travel	xNone		
8	Patents planned, issued or	_xNone		
	pending			
0	Participation on a Data	y None		
9	Safety Monitoring Board or	xNone		_
	Advisory Board			-
10	Leadership or fiduciary role	x None		
	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	x_None		
12	Receipt of equipment,	_xNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	x None		
13	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one.			

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.